Sanifit raises €36.6 million to advance SNF472
8 September 2015 | By Victoria White
SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in patients with end stage renal disease...
List view / Grid view
News
Opdivo demonstrates sustained survival results in squamous NSCLC
8 September 2015 | By Victoria White
In two studies, Opdivo showed an estimated 18 month overall survival rate of 27% to 28% in patients with previously treated squamous non-small cell lung cancer (NSCLC)...
Responsible Person training supported by MHRA Inspectorate
7 September 2015 | By Victoria White
The MHRA has said it is now seeing greater appreciation among pharmaceutical sector companies of the skills required for the essential Responsible Person role...
Cherwell appoints Harshad Joshi as new Quality Manager
7 September 2015 | By Cherwell Laboratories
Company maintains focus on quality to meet customer expectations...
23 drugs to be axed from the Cancer Drug Fund
7 September 2015 | By Victoria White
The announcement follows a review that found that CDF spending would rise to around £410 million for this year - an over-spend of £70m from the budget set in April 2015...
NICE recommends melanoma drug pembrolizumab
7 September 2015 | By Victoria White
NICE has recommended that pembrolizumab is made available on the NHS as a treatment for some patients with advanced melanoma which is either unresectable or metastatic...
Celyad appoints Dr Debasish Roychowdhury as non-executive director
7 September 2015 | By Victoria White
Dr Roychowdury brings over 15 years of comprehensive pharmaceutical industry experience and 14 years of patient care and academic research to the role with Celyad...
Faron announces intention to float on AIM
7 September 2015 | By Victoria White
Faron's admission to AIM will support development of its lead candidate, Traumakine, into a Phase III Study and the development of its preclinical cancer immunotherapy candidate, Clevegen...
EC approves multiple myeloma treatment Farydak
4 September 2015 | By Victoria White
The EC has approved Farydak in combination with bortezomib and dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma...
NICE recommends RoActemra for severe rheumatoid arthritis
4 September 2015 | By Victoria White
RoActemra has been recommended by NICE for the treatment of patients with severe rheumatoid arthritis whose disease has not responded to intensive therapy with a combination of cDMARDs...
FDA approves label expansion for AstraZeneca’s Brilinta
4 September 2015 | By Victoria White
The FDA has approved Brilinta tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year...
FDA grants breakthrough therapy designation to Roche’s ACE910
4 September 2015 | By Victoria White
Breakthrough therapy designation has been granted to ACE910 for the prophylactic treatment of people with haemophilia A with factor VIII inhibitors...
Allergan to acquire glaucoma treatment company AqueSys
4 September 2015 | By Victoria White
Allergan is to acquire AqueSys for a $300 million upfront payment and milestone payments related to AqueSys' lead development programmes, including XEN45...
Branded ACS therapies to grab market share from generic drugs
4 September 2015 | By Victoria White
While generic acute coronary syndrome (ACS) drugs currently lead in market revenues, the share of branded therapeutics is expected to increase to more than 60% of the total market by 2019...
Extent of data breaches in pharmaceutical sector revealed
3 September 2015 | By Victoria White
The extent of data breaches in the pharmaceutical sector has been revealed by a survey that shows 60% have lost important data...
